Diplomat Pharmacy (DPLO) PT Cut to $14 at Cowen

Cowen lowered its price target on Diplomat Pharmacy (NYSE: DPLO) to $14.00 (from $18.00) as the company expects 2016 results to come in towards the lower-end of guidance.

Analyst Charles Rhyee commented, "DPLO now expects 2016 results to come in towards the lower-end of guidance. More importantly mgmts expects 2017 to be softer than expected due to various challenges. However mgmt looks to drive growth organically and inorganically as evidence by its acq. of Affinity Biotech which is largely immaterial in contribution but expands DPLO s footprint into Houston and NYC as well as expands margins.."

For an analyst ratings summary and ratings history on Diplomat Pharmacy click here. For more ratings news on Diplomat Pharmacy click here.

Shares of Diplomat Pharmacy closed at $12.50 yesterday.

You May Also Be Interested In

• Jefferies Upgrades Husqvarna AB (HUSQB:SS) to Buy
• Neste Oyj (NESTE:FH) (NTOIY) PT Lowered to EUR28 at Barclays
• Morgan Stanley Upgrades EPAM Systems (EPAM) to Equalweight